[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100659817":3},{"organization":4,"outcomesModule":7,"designInfo":42,"detailedDescription":45,"studyPopulation":46,"armGroups":47,"interventions":53,"overallOfficials":58,"centralContacts":62,"locations":41,"responsibleParty":68,"collaborators":41,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":41,"eligibilityCriteria":76,"healthyVolunteers":72,"sex":77,"minAge":41,"maxAge":41,"enrollmentInfo":78,"targetDuration":41,"studyType":81,"phases":41,"briefSummary":82,"conditions":83,"keywords":41,"overallStatus":85,"whyStopped":41,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":41},{"fullName":5,"class":6},"Takeda","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":28,"otherOutcomes":41},[9,13,16,19,22,25],{"measure":10,"description":11,"timeFrame":12},"Percentage of Participating Physicians Correctly Identifying the Prespecified Diagnostic Criteria and Risk-Classification Factors for PV in Standardized Clinical Vignettes","For each prespecified diagnostic criterion and risk-classification factor, the percentage of participating physicians selecting the protocol-defined correct response will be reported.","At completion of the approximately 30-minute survey session (up to 10 months)",{"measure":14,"description":15,"timeFrame":12},"Distribution of Physician Responses Regarding Early Cytoreductive Treatment in PV","The number of participating physicians selecting each response category for the statement 'Early cytoreductive therapy is underutilized in PV management in my region' will be reported using a 5-point Likert agreement scale ranging from 1, 'Strongly disagree,' to 5, 'Strongly agree.' Higher scores indicate greater agreement with the statement. Treatment choices made in the standardized PV clinical vignettes will also be summarized descriptively.",{"measure":17,"description":18,"timeFrame":12},"Concordance of Physician-Reported Diagnostic and Treatment Decisions With Prespecified PV Guideline-Based Criteria","For each applicable survey or vignette decision, the number of participating physicians whose response is concordant with the protocol-defined guideline-based criterion will be reported.",{"measure":20,"description":21,"timeFrame":12},"Distribution of Self-Reported Rate of Adherence to International Guidelines in Diagnostic and Therapeutic Decisions","For each guideline category, the number of participating physicians reporting 'Always,' 'Often,' or 'Rarely' will be summarized. The international guideline most commonly used will also be reported.",{"measure":23,"description":24,"timeFrame":12},"Distribution of Physician-Reported Phlebotomy Use and Cytoreductive Treatment in Current PV Management","The distribution of the estimated percentage of physicians' patients currently managed with phlebotomy alone, phlebotomy plus cytoreductive therapy, ruxolitinib, or other therapies will be summarized.",{"measure":26,"description":27,"timeFrame":12},"Number of Physicians by Reported HCT Monitoring Frequencies and HCT Thresholds for Treatment Escalation","HCT monitoring intervals will be summarized separately for low- and high-risk PV. Physician-reported HCT thresholds for treatment escalation will be summarized descriptively.",[29,32,35,38],{"measure":30,"description":31,"timeFrame":12},"Percentage of Physicians Reporting Use of Diagnostic Procedures and Treatment Modalities Used for PV Management","The percentage of participating physicians reporting use of each prespecified diagnostic procedure and treatment modality, including phlebotomy, aspirin, cytoreductive treatment, and individual treatment agents, will be reported. For each prespecified diagnostic or monitoring tool, the number and percentage of physicians reporting 'Always,' 'Often,' or 'Rarely' will be reported separately for initial diagnosis and ongoing monitoring.",{"measure":33,"description":34,"timeFrame":12},"Percentage of Physicians Reporting Factors Influencing Clinical Decision-Making in PV Management","The percentage of participating physicians selecting each prespecified factor, including physician experience, resource limitations, patient characteristics, treatment preferences, and access-related considerations, as most important in their decision to change PV treatment will be reported.",{"measure":36,"description":37,"timeFrame":12},"Percentage of Physicians Selecting Each Treatment-Management Option in low- and High-Risk PV Clinical Vignettes","Percentage of physicians selecting each prespecified classification and treatment-management option in response to low- and high-risk PV clinical vignettes will be reported. Responses will be descriptively aggregated to summarize commonly reported sequences of treatment without ranking treatment sequences, identifying an optimal sequence, or making causal inferences.",{"measure":39,"description":40,"timeFrame":12},"Percentage of Physicians Reporting Systemic Barriers to Optimal PV Care and Their Perceived Impact","For each prespecified barrier to early cytoreductive therapy, the percentage of physicians rating its impact as high, moderate, or low will be reported. The barriers selected among the top three barriers to optimal PV care will be summarized separately.",null,{"allocation":41,"interventionModel":41,"interventionModelDescription":41,"primaryPurpose":41,"observationalModel":43,"timePerspective":44,"maskingInfo":41},"OTHER","CROSS_SECTIONAL","This study is a non-interventional, cross-sectional physician survey study employing a Knowledge, Attitudes and Practices (KAP) framework and standardized Polycythemia Vera clinical vignettes. Data are collected through a single interviewer-led session with practicing hematologists and hemato-oncologists. The study evaluates physician diagnostic and treatment decision-making patterns and does not involve patient enrollment, patient-level data collection, treatment assignment, or longitudinal follow-up.","Licensed hematologists and hemato-oncologists who are board-certified or independently practicing and actively involved in diagnosing or managing patients with PV will be enrolled.",[48],{"label":49,"type":41,"description":50,"interventionNames":51},"Physician Survey","Eligible hematologists and hemato-oncologists will participate in a single survey session lasting approximately 30 minutes. The session will use standardized PV clinical vignettes and a combination of open and closed-ended questions to assess physicians' KAP and clinical decision making. All data will be collected through audio-recorded interviews (where applicable) and\u002For typed narrative entries in a secure online platform. No clinical intervention will be administered, and no follow-up will be conducted.",[52],"Other: No Intervention",[54],{"type":43,"name":55,"description":56,"armGroupLabels":57,"otherNames":41},"No Intervention","No intervention will be administered in this study.",[49],[59],{"name":60,"affiliation":5,"role":61},"Study Director","STUDY_DIRECTOR",[63],{"name":64,"role":65,"phone":66,"phoneExt":41,"email":67},"Takeda Contact","CONTACT","+1-877-825-3327","medinfoUS@takeda.com",{"type":69,"investigatorFullName":41,"investigatorTitle":41,"investigatorAffiliation":41,"oldNameTitle":41,"oldOrganization":41},"SPONSOR","100659817","a-study-to-better-understand-the-diagnosis-and-treatment-of-polycythaemia-vera-100659817",false,"NCT07868081","A Study to Better Understand the Diagnosis and Treatment of Polycythaemia Vera","Knowledge, Attitudes and Practices Through Unified Real-world Experimental Vignettes in Polycythemia Vera (PV): KAPTURE-PV, a Multi-Country Vignette-Based Observational Study","This study is based on physician responses to standardized clinical vignettes. Therefore, eligibility applies to participating physicians:\n\nInclusion Criteria:\n\n* Board-certified or practicing hematology specialists actively managing PV patients.\n* Currently practicing in a hospital or clinic setting in the Kingdom of Saudi Arabia or Ukraine or Türkiye.\n* Minimum of 3 years of experience in the management of myeloproliferative neoplasms and\u002For hematological malignancies. Actively managing a minimum number of PV patients, defined as either:\n* Has managed at least 10 patients with PV during the past 3 to 5 years, or at least 3 to 5 patients with PV during the past 12 months.\n* Willing and able to provide informed consent and participate in a standardized survey and vignette assessment in a language in which the approved study materials are available, including English, Turkish, or Ukrainian, as applicable to the participating country.\n\nExclusion Criteria:\n\n* Physicians not currently involved in the diagnosis or management of PV patients.\n* Medical trainees, residents, or fellows not yet board-certified or independently practicing.\n* Practicing outside of KSA or Ukraine or Türkiye.\n* Unwilling or unable to provide informed consent or complete the study procedures.","ALL",{"count":79,"type":80},90,"ESTIMATED","OBSERVATIONAL","PV is a rare, long-term blood cancer that causes the body to make too many blood cells. This can make the blood thicker than normal and the risk of blood clots higher. People with PV often experience symptoms that can affect their daily lives. Understanding how doctors diagnose and treat PV in everyday medical practice in a certain country can help find the differences in knowledge, diagnosis, and treatment of PV across countries.\n\nThis study will not review or collect data from actual people with PV. It will collect information on the diagnosis and treatment of PV using a standard set of questions on and examples of fictional (unreal) people with PV. This is called clinical vignette. The study will ask doctors from several countries to complete this survey.\n\nThe main aim of this study is to better understand how well doctors know about and diagnose PV and how they treat PV in certain countries.\n\nOther aims are to better understand how PV is managed and treated in everyday medical practice across countries. This includes which treatment people with PV receive once they are diagnosed and how access to medicines and healthcare services and other factors affects a doctor's treatment decisions for PV.",[84],"Polycythemia Vera","NOT_YET_RECRUITING","2026-10-05",{"date":88,"type":89},"2026-10-09","ACTUAL",{"date":91,"type":80},"2026-12-01",{"date":93,"type":80},"2027-03-01",{"name":5,"class":6}]